Incidence and Risk of Second Primary Malignancies After Treatment for Papillary Thyroid Cancer: A Single Institution Study.

IF 1.6 4区医学 Q4 ONCOLOGY

American Journal of Clinical Oncology-Cancer Clinical Trials Pub Date : 2025-07-01 DOI:10.1097/COC.0000000000001228

Katelyn R Ward, Heba Elassar, Jacquelyn Pastewski, Morta Lapkus, Diane Studzinski, Fionna Sun, Jordan Reilly, Peter Czako, Sapna Nagar

{"title":"Incidence and Risk of Second Primary Malignancies After Treatment for Papillary Thyroid Cancer: A Single Institution Study.","authors":"Katelyn R Ward, Heba Elassar, Jacquelyn Pastewski, Morta Lapkus, Diane Studzinski, Fionna Sun, Jordan Reilly, Peter Czako, Sapna Nagar","doi":"10.1097/COC.0000000000001228","DOIUrl":null,"url":null,"abstract":"Objectives: Papillary thyroid cancer (PTC) patients develop nonthyroid second primary malignancy (SPM) at a rate higher than the general population. We aimed to investigate the incidence of SPM, demographic risk factors, and relationship with RAIT among PTC patients.Methods: A retrospective review was performed of PTC patients who underwent thyroid surgery at a single institution from 1/2007 to 1/2011.Results: Of 528 patients, 40 (7.6%) were diagnosed with SPM (SPM+) over a median follow-up of 9.3 years. The standardized incidence ratio was 1.3 using demographic-adjusted SEER data. Median time to SPM diagnosis was 4.0 years (IQR 2.0, 6.7). Breast cancer was the most common SPM, occurring in 12 patients (30%). RAIT use and RAIT dose were not associated with SPM. There was no significant association between SPM and mortality (6.3% SPM+ vs. 3.1% SPM-, P=0.300). Older age (median 56.5 vs. 49.0 y, P=0.004), prior personal history of cancer (22.5% vs. 11.3%, P=0.036), and family history of cancer (70.0% vs. 42.8%, P<0.001) were associated with SPM+, but none were identified as independent risk factors.Conclusions: This study did not find any association between SPM and RAIT in PTC patients. Factors other than RAIT, such as age and personal or family history of cancer were associated with SPM risk in PTC patients.","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Clinical Oncology-Cancer Clinical Trials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COC.0000000000001228","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Papillary thyroid cancer (PTC) patients develop nonthyroid second primary malignancy (SPM) at a rate higher than the general population. We aimed to investigate the incidence of SPM, demographic risk factors, and relationship with RAIT among PTC patients.

Methods: A retrospective review was performed of PTC patients who underwent thyroid surgery at a single institution from 1/2007 to 1/2011.

Results: Of 528 patients, 40 (7.6%) were diagnosed with SPM (SPM+) over a median follow-up of 9.3 years. The standardized incidence ratio was 1.3 using demographic-adjusted SEER data. Median time to SPM diagnosis was 4.0 years (IQR 2.0, 6.7). Breast cancer was the most common SPM, occurring in 12 patients (30%). RAIT use and RAIT dose were not associated with SPM. There was no significant association between SPM and mortality (6.3% SPM+ vs. 3.1% SPM-, P=0.300). Older age (median 56.5 vs. 49.0 y, P=0.004), prior personal history of cancer (22.5% vs. 11.3%, P=0.036), and family history of cancer (70.0% vs. 42.8%, P<0.001) were associated with SPM+, but none were identified as independent risk factors.

Conclusions: This study did not find any association between SPM and RAIT in PTC patients. Factors other than RAIT, such as age and personal or family history of cancer were associated with SPM risk in PTC patients.

查看原文本刊更多论文

甲状腺乳头状癌治疗后第二原发恶性肿瘤的发病率和风险：一项单机构研究。

目的：甲状腺乳头状癌（PTC）患者发生非甲状腺第二原发性恶性肿瘤（SPM）的比率高于一般人群。我们的目的是调查PTC患者中SPM的发生率、人口统计学危险因素以及与RAIT的关系。方法：回顾性分析2007年1月至2011年1月在同一医院接受甲状腺手术的PTC患者。结果：在528例患者中，40例（7.6%）被诊断为SPM (SPM+)，中位随访时间为9.3年。采用人口统计学校正的SEER数据，标准化发病率为1.3。到SPM诊断的中位时间为4.0年（IQR 2.0, 6.7）。乳腺癌是最常见的SPM，发生在12例患者中（30%）。RAIT的使用和剂量与SPM无关。SPM与死亡率之间无显著相关性（6.3% SPM+ vs 3.1% SPM-， P=0.300）。年龄（中位数56.5比49.0岁，P=0.004）、既往个人癌症史（22.5%比11.3%，P=0.036）和癌症家族史（70.0%比42.8%）。结论：本研究未发现PTC患者SPM和RAIT之间存在任何关联。除RAIT外的其他因素，如年龄、个人或家族癌症史与PTC患者的SPM风险相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Clinical Oncology-Cancer Clinical Trials 医学-肿瘤学

CiteScore

4.90

自引率

0.00%

发文量

130

审稿时长

4-8 weeks

期刊介绍： American Journal of Clinical Oncology is a multidisciplinary journal for cancer surgeons, radiation oncologists, medical oncologists, GYN oncologists, and pediatric oncologists. The emphasis of AJCO is on combined modality multidisciplinary loco-regional management of cancer. The journal also gives emphasis to translational research, outcome studies, and cost utility analyses, and includes opinion pieces and review articles. The editorial board includes a large number of distinguished surgeons, radiation oncologists, medical oncologists, GYN oncologists, pediatric oncologists, and others who are internationally recognized for expertise in their fields.